TY - JOUR
T1 - International consensus guidance for management of myasthenia gravis: Executive summary
AU - Sanders, Donald B.
AU - Wolfe, Gil I.
AU - Benatar, Michael
AU - Evoli Stampanoni-B, Amelia
AU - Gilhus, Nils E.
AU - Illa, Isabel
AU - Kuntz, Nancy
AU - Massey, Janice M.
AU - Melms, Arthur
AU - Murai, Hiroyuki
AU - Nicolle, Michael
AU - Palace, Jacqueline
AU - Richman, David P.
AU - Verschuuren, Jan
AU - Narayanaswami, Pushpa
PY - 2016
Y1 - 2016
N2 - Objective: To develop formal consensus-based guidance for the management of myasthenia gravis (MG). Methods: In October 2013, the Myasthenia Gravis Foundation of America appointed a Task Force to develop treatment guidance for MG, and a panel of 15 international experts was convened. The RAND/UCLA appropriateness methodology was used to develop consensus guidance statements. Definitions were developed for goals of treatment, minimal manifestations, remission, ocular MG, impending crisis, crisis, and refractory MG. An in-person panel meeting then determined 7 treatment topics to be addressed. Initial guidance statements were developed from literature summaries. Three rounds of anonymous e-mail votes were used to attain consensus on guidance statements modified on the basis of panel input. Results: Guidance statements were developed for symptomatic and immunosuppressive treatments, IV immunoglobulin and plasma exchange, management of impending and manifest myasthenic crisis, thymectomy, juvenile MG, MG associated with antibodies to muscle-specific tyrosine kinase, and MG in pregnancy. Conclusion: This is an international formal consensus of MG experts intended to be a guide for clinicians caring for patients with MG worldwide.
AB - Objective: To develop formal consensus-based guidance for the management of myasthenia gravis (MG). Methods: In October 2013, the Myasthenia Gravis Foundation of America appointed a Task Force to develop treatment guidance for MG, and a panel of 15 international experts was convened. The RAND/UCLA appropriateness methodology was used to develop consensus guidance statements. Definitions were developed for goals of treatment, minimal manifestations, remission, ocular MG, impending crisis, crisis, and refractory MG. An in-person panel meeting then determined 7 treatment topics to be addressed. Initial guidance statements were developed from literature summaries. Three rounds of anonymous e-mail votes were used to attain consensus on guidance statements modified on the basis of panel input. Results: Guidance statements were developed for symptomatic and immunosuppressive treatments, IV immunoglobulin and plasma exchange, management of impending and manifest myasthenic crisis, thymectomy, juvenile MG, MG associated with antibodies to muscle-specific tyrosine kinase, and MG in pregnancy. Conclusion: This is an international formal consensus of MG experts intended to be a guide for clinicians caring for patients with MG worldwide.
KW - Myasthenia gravis, thymectomy, immunosuppressive therapy
KW - Myasthenia gravis, thymectomy, immunosuppressive therapy
UR - http://hdl.handle.net/10807/94689
UR - http://www.neurology.org
U2 - 10.1212/WNL.0000000000002790
DO - 10.1212/WNL.0000000000002790
M3 - Article
SN - 0028-3878
VL - 87
SP - 419
EP - 425
JO - Neurology
JF - Neurology
ER -